|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EIF3F |
Gene summary for EIF3F |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EIF3F | Gene ID | 8665 |
| Gene name | eukaryotic translation initiation factor 3 subunit F | |
| Gene Alias | EIF3S5 | |
| Cytomap | 11p15.4 | |
| Gene Type | protein-coding | GO ID | GO:0001732 | UniProtAcc | O00303 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8665 | EIF3F | GSM4909280 | Human | Breast | Precancer | 4.06e-02 | -5.85e-01 | 0.0305 |
| 8665 | EIF3F | GSM4909287 | Human | Breast | IDC | 1.49e-06 | -3.85e-01 | 0.2057 |
| 8665 | EIF3F | GSM4909294 | Human | Breast | IDC | 5.17e-10 | -2.40e-01 | 0.2022 |
| 8665 | EIF3F | GSM4909296 | Human | Breast | IDC | 4.31e-28 | 1.38e-01 | 0.1524 |
| 8665 | EIF3F | GSM4909297 | Human | Breast | IDC | 1.74e-36 | -2.46e-01 | 0.1517 |
| 8665 | EIF3F | GSM4909301 | Human | Breast | IDC | 3.14e-06 | -3.45e-01 | 0.1577 |
| 8665 | EIF3F | GSM4909302 | Human | Breast | IDC | 1.43e-02 | -2.86e-01 | 0.1545 |
| 8665 | EIF3F | GSM4909305 | Human | Breast | IDC | 4.30e-02 | 2.60e-01 | 0.0436 |
| 8665 | EIF3F | GSM4909307 | Human | Breast | IDC | 9.14e-03 | 1.07e-01 | 0.1569 |
| 8665 | EIF3F | GSM4909308 | Human | Breast | IDC | 2.86e-10 | 3.67e-01 | 0.158 |
| 8665 | EIF3F | GSM4909309 | Human | Breast | IDC | 7.21e-03 | -1.15e-01 | 0.0483 |
| 8665 | EIF3F | GSM4909311 | Human | Breast | IDC | 6.55e-54 | -4.33e-01 | 0.1534 |
| 8665 | EIF3F | GSM4909312 | Human | Breast | IDC | 3.28e-38 | 2.96e-01 | 0.1552 |
| 8665 | EIF3F | GSM4909313 | Human | Breast | IDC | 5.11e-05 | -9.98e-02 | 0.0391 |
| 8665 | EIF3F | GSM4909315 | Human | Breast | IDC | 6.89e-06 | -3.91e-01 | 0.21 |
| 8665 | EIF3F | GSM4909316 | Human | Breast | IDC | 9.38e-04 | -4.64e-01 | 0.21 |
| 8665 | EIF3F | GSM4909319 | Human | Breast | IDC | 1.48e-69 | -5.16e-01 | 0.1563 |
| 8665 | EIF3F | GSM4909320 | Human | Breast | IDC | 5.97e-06 | -3.73e-01 | 0.1575 |
| 8665 | EIF3F | GSM4909321 | Human | Breast | IDC | 8.04e-26 | -3.69e-02 | 0.1559 |
| 8665 | EIF3F | M2 | Human | Breast | IDC | 1.97e-02 | -2.87e-01 | 0.21 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000641311 | Stomach | CAG with IM | translational initiation | 20/1050 | 118/18723 | 8.51e-06 | 2.96e-04 | 20 |
| GO:007182611 | Stomach | CAG with IM | ribonucleoprotein complex subunit organization | 30/1050 | 227/18723 | 1.12e-05 | 3.70e-04 | 30 |
| GO:002261311 | Stomach | CAG with IM | ribonucleoprotein complex biogenesis | 49/1050 | 463/18723 | 1.47e-05 | 4.77e-04 | 49 |
| GO:002261811 | Stomach | CAG with IM | ribonucleoprotein complex assembly | 29/1050 | 220/18723 | 1.64e-05 | 5.16e-04 | 29 |
| GO:000173211 | Stomach | CAG with IM | formation of cytoplasmic translation initiation complex | 5/1050 | 16/18723 | 1.43e-03 | 1.64e-02 | 5 |
| GO:000218311 | Stomach | CAG with IM | cytoplasmic translational initiation | 7/1050 | 34/18723 | 2.42e-03 | 2.39e-02 | 7 |
| GO:000218121 | Stomach | CSG | cytoplasmic translation | 62/1034 | 148/18723 | 6.36e-39 | 3.36e-35 | 62 |
| GO:001603221 | Stomach | CSG | viral process | 53/1034 | 415/18723 | 1.07e-08 | 9.41e-07 | 53 |
| GO:000641321 | Stomach | CSG | translational initiation | 20/1034 | 118/18723 | 6.78e-06 | 2.49e-04 | 20 |
| GO:007182621 | Stomach | CSG | ribonucleoprotein complex subunit organization | 30/1034 | 227/18723 | 8.31e-06 | 2.97e-04 | 30 |
| GO:002261321 | Stomach | CSG | ribonucleoprotein complex biogenesis | 49/1034 | 463/18723 | 9.79e-06 | 3.36e-04 | 49 |
| GO:002261821 | Stomach | CSG | ribonucleoprotein complex assembly | 29/1034 | 220/18723 | 1.23e-05 | 4.17e-04 | 29 |
| GO:000173221 | Stomach | CSG | formation of cytoplasmic translation initiation complex | 5/1034 | 16/18723 | 1.33e-03 | 1.56e-02 | 5 |
| GO:000218321 | Stomach | CSG | cytoplasmic translational initiation | 7/1034 | 34/18723 | 2.22e-03 | 2.25e-02 | 7 |
| GO:000218131 | Stomach | CAG | cytoplasmic translation | 60/552 | 148/18723 | 9.60e-53 | 4.29e-49 | 60 |
| GO:001603231 | Stomach | CAG | viral process | 37/552 | 415/18723 | 2.37e-09 | 4.06e-07 | 37 |
| GO:002261331 | Stomach | CAG | ribonucleoprotein complex biogenesis | 39/552 | 463/18723 | 4.33e-09 | 6.72e-07 | 39 |
| GO:002261831 | Stomach | CAG | ribonucleoprotein complex assembly | 24/552 | 220/18723 | 3.77e-08 | 4.21e-06 | 24 |
| GO:007182631 | Stomach | CAG | ribonucleoprotein complex subunit organization | 24/552 | 227/18723 | 6.88e-08 | 7.14e-06 | 24 |
| GO:000641331 | Stomach | CAG | translational initiation | 15/552 | 118/18723 | 2.02e-06 | 1.14e-04 | 15 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EIF3F | insertion | Nonsense_Mutation | novel | c.742_743insAGTAAAGTATAGATCCAGGTATATAATTGACATA | p.Gly248GlufsTer2 | p.G248Efs*2 | O00303 | protein_coding | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| EIF3F | SNV | Missense_Mutation | novel | c.317N>G | p.Tyr106Cys | p.Y106C | O00303 | protein_coding | deleterious(0.05) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| EIF3F | SNV | Missense_Mutation | novel | c.941N>G | p.Gln314Arg | p.Q314R | O00303 | protein_coding | tolerated(0.09) | benign(0.268) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| EIF3F | SNV | Missense_Mutation | c.626G>A | p.Gly209Asp | p.G209D | O00303 | protein_coding | tolerated(0.1) | benign(0.01) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| EIF3F | SNV | Missense_Mutation | rs371389618 | c.629N>A | p.Arg210His | p.R210H | O00303 | protein_coding | tolerated(0.24) | benign(0.051) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| EIF3F | SNV | Missense_Mutation | c.833N>A | p.Arg278His | p.R278H | O00303 | protein_coding | tolerated(0.16) | benign(0.01) | TCGA-D5-6924-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| EIF3F | SNV | Missense_Mutation | c.236N>A | p.Gly79Asp | p.G79D | O00303 | protein_coding | tolerated(0.17) | benign(0.027) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| EIF3F | SNV | Missense_Mutation | c.773N>T | p.Ser258Ile | p.S258I | O00303 | protein_coding | deleterious(0.02) | benign(0.248) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| EIF3F | SNV | Missense_Mutation | novel | c.440N>T | p.Ala147Val | p.A147V | O00303 | protein_coding | tolerated(0.07) | benign(0.141) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| EIF3F | SNV | Missense_Mutation | rs200315934 | c.29N>T | p.Ala10Val | p.A10V | O00303 | protein_coding | tolerated_low_confidence(0.3) | benign(0) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |